Research graph
References from Safety management of anti TROP2 ADCs in patients with breast cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Global patterns and trends in breast cancer incidence and mortality across 185 countries
10.1038/s41591-025-03502-3 · 2025 · External reference
Unlocking the potential of antibody–drug conjugates for cancer therapy
10.1038/s41571-021-00470-8 · 2021 · External reference
Antibody–drug conjugates: smart chemotherapy delivery across tumor histologies
2022 · External reference
Novel treatment approaches utilizing antibody−drug conjugates in breast cancer
10.1038/s41523-025-00743-w · 2025 · External reference
Trop-2 is a determinant of breast cancer survival
10.1371/journal.pone.0096993 · 2014 · External reference
Trop2-targeted therapy in breast cancer
10.1186/s40364-024-00633-6 · 2024 · External reference
First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors
10.1158/1078-0432.ccr-14-3321 · 2015 · External reference
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
10.1038/s41571-023-00783-w · 2023 · External reference
Prevalence of treatment-related adverse events (TRAEs) with antibody–drug conjugates in metastatic breast cancer patients: a systematic review and meta-analysis
10.1016/j.critrevonc.2024.104527 · 2024 · External reference
Adverse events and impact on quality of life of antibody–drug conjugates in the treatment of metastatic breast cancer: a systematic review and meta-analysis
10.1111/eci.70001 · 2025 · External reference
Emerging toxicities of antibody-drug conjugates for breast cancer: clinical prioritization of adverse events from the FDA Adverse Event Reporting System
10.1007/s11523-024-01058-9 · 2024 · External reference
Sacituzumab Govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody–drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers
10.1021/acs.bioconjchem.5b00223 · 2015 · External reference
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
10.18632/oncotarget.4318 · 2015 · External reference
Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer
10.1056/nejmoa1814213 · 2019 · External reference
Sacituzumab govitecan in metastatic triple-negative breast cancer
10.1056/nejmoa2028485 · 2021 · External reference
Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression
10.1200/jco.23.01409 · 2024 · External reference
Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
10.21037/atm-22-6266 · 2023 · External reference
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
10.1016/s0140-6736(23)01245-x · 2023 · External reference
Sacituzumab govitecan in untreated, advanced triple-negative breast cancer
10.1056/nejmoa2511734 · 2025 · External reference
Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer
10.1056/nejmoa2508959 · 2026 · External reference
Datopotamab deruxtecan, a novel TROP2-directed antibody–drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells
10.1158/1535-7163.mct-21-0206 · 2021 · External reference
Datopotamab deruxtecan in advanced or metastatic HR+/HER2– and triple-negative breast cancer: results from the Phase I TROPION-PanTumor01 Study
10.1200/jco.23.01909 · 2024 · External reference
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor–positive human epidermal growth factor receptor 2–negative breast cancer: primary results from TROPION-Breast01
10.1200/jco.24.00920 · 2025 · External reference
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study
10.1016/j.annonc.2025.12.017 · 2026 · External reference
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
10.1016/j.annonc.2026.03.008 · 2026 · External reference
FDA approval summary: datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer
10.1158/1078-0432.ccr-25-1388 · 2025 · External reference
Exploring the next generation of antibody–drug conjugates
10.1038/s41571-023-00850-2 · 2024 · External reference
Mechanisms of ADC toxicity and strategies to increase ADC tolerability
10.3390/cancers15030713 · 2023 · External reference
Expression of Trop2 cell surface glycoprotein in normal and tumor tissues
10.1369/0022155411410430 · 2011 · External reference
Tumor-associated calcium signal transducer 2 is required for the proper subcellular localization of claudin 1 and 7
10.2353/ajpath.2010.100149 · 2010 · External reference
Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis
2025 · External reference
Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab–drug conjugate, in monkeys
10.1111/cas.14686 · 2020 · External reference
Perivascular niche–resident alveolar macrophages promote interstitial pneumonitis related to trastuzumab deruxtecan treatment
10.1158/0008-5472.can-24-2021 · 2025 · External reference
Potential mechanisms of interstitial lung disease induced by antibody–drug conjugates based on quantitative analysis of drug distribution
10.1158/1535-7163.mct-24-0267 · 2025 · External reference
Sacituzumab govitecan in hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer
10.1200/jco.22.01002 · 2022 · External reference
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
10.1038/s41523-022-00467-1 · 2022 · External reference
Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe
10.1093/oncolo/oyag014 · 2026 · External reference
Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany
10.1177/17588359231200454 · 2023 · External reference
Real-world evidence of sacituzumab govitecan in metastatic triple-negative breast cancer: an updated multicenter analysis
10.1016/j.esmoop.2026.108251 · 2026 · External reference
Pre-therapeutic UGT1A1 genotyping in breast cancer patients receiving sacituzumab govitecan to improve safety: a meta-analysis and recommendation
10.1111/cts.70462 · 2026 · External reference
Canadian expert recommendations on safety overview and toxicity management strategies for sacituzumab govitecan based on use in metastatic triple-negative breast cancer
10.3390/curroncol31090422 · 2024 · External reference
Sacituzumab govitecan for metastatic triple-negative breast cancer: clinical overview and management of potential toxicities
10.1002/onco.13878 · 2021 · External reference
Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multicenter real-world analysis
10.3389/fonc.2024.1362641 · 2024 · External reference
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study
10.1016/j.esmoop.2026.108330 · 2026 · External reference
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan
10.1016/j.ctrv.2024.102720 · 2024 · External reference
US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan
2025 · External reference
Datopotamab deruxtecan–associated select adverse events: clinical practices and institutional protocols on prophylaxis, monitoring, and management
10.1093/oncolo/oyaf225 · 2025 · External reference
Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer
10.1056/nejmoa2508959 · 2026 · External reference
Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study
10.1016/j.annonc.2026.05.693 · 2026 · External reference
Sacituzumab govitecan for metastatic triple-negative breast cancer: clinical overview and management of potential toxicities
10.1002/onco.13878 · ExternalCitation · doi-reference
Emerging toxicities of antibody-drug conjugates for breast cancer: clinical prioritization of adverse events from the FDA Adverse Event Reporting System
10.1007/s11523-024-01058-9 · ExternalCitation · doi-reference
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study
10.1016/j.annonc.2025.12.017 · ExternalCitation · doi-reference
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
10.1016/j.annonc.2026.03.008 · ExternalCitation · doi-reference
Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study
10.1016/j.annonc.2026.05.693 · ExternalCitation · doi-reference
Prevalence of treatment-related adverse events (TRAEs) with antibody–drug conjugates in metastatic breast cancer patients: a systematic review and meta-analysis
10.1016/j.critrevonc.2024.104527 · ExternalCitation · doi-reference
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan
10.1016/j.ctrv.2024.102720 · ExternalCitation · doi-reference
Real-world evidence of sacituzumab govitecan in metastatic triple-negative breast cancer: an updated multicenter analysis
10.1016/j.esmoop.2026.108251 · ExternalCitation · doi-reference
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study
10.1016/j.esmoop.2026.108330 · ExternalCitation · doi-reference
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
10.1016/s0140-6736(23)01245-x · ExternalCitation · doi-reference
Sacituzumab Govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody–drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers
10.1021/acs.bioconjchem.5b00223 · ExternalCitation · doi-reference
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
10.1038/s41523-022-00467-1 · ExternalCitation · doi-reference
Novel treatment approaches utilizing antibody−drug conjugates in breast cancer
10.1038/s41523-025-00743-w · ExternalCitation · doi-reference
Unlocking the potential of antibody–drug conjugates for cancer therapy
10.1038/s41571-021-00470-8 · ExternalCitation · doi-reference
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
10.1038/s41571-023-00783-w · ExternalCitation · doi-reference
Exploring the next generation of antibody–drug conjugates
10.1038/s41571-023-00850-2 · ExternalCitation · doi-reference
Global patterns and trends in breast cancer incidence and mortality across 185 countries
10.1038/s41591-025-03502-3 · ExternalCitation · doi-reference
Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer
10.1056/nejmoa1814213 · ExternalCitation · doi-reference
Sacituzumab govitecan in metastatic triple-negative breast cancer
10.1056/nejmoa2028485 · ExternalCitation · doi-reference
Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer
10.1056/nejmoa2508959 · ExternalCitation · doi-reference
Sacituzumab govitecan in untreated, advanced triple-negative breast cancer
10.1056/nejmoa2511734 · ExternalCitation · doi-reference
Datopotamab deruxtecan–associated select adverse events: clinical practices and institutional protocols on prophylaxis, monitoring, and management
10.1093/oncolo/oyaf225 · ExternalCitation · doi-reference
Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe
10.1093/oncolo/oyag014 · ExternalCitation · doi-reference
Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab–drug conjugate, in monkeys
10.1111/cas.14686 · ExternalCitation · doi-reference
Pre-therapeutic UGT1A1 genotyping in breast cancer patients receiving sacituzumab govitecan to improve safety: a meta-analysis and recommendation
10.1111/cts.70462 · ExternalCitation · doi-reference
Adverse events and impact on quality of life of antibody–drug conjugates in the treatment of metastatic breast cancer: a systematic review and meta-analysis
10.1111/eci.70001 · ExternalCitation · doi-reference
Perivascular niche–resident alveolar macrophages promote interstitial pneumonitis related to trastuzumab deruxtecan treatment
10.1158/0008-5472.can-24-2021 · ExternalCitation · doi-reference
First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors
10.1158/1078-0432.ccr-14-3321 · ExternalCitation · doi-reference
FDA approval summary: datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer
10.1158/1078-0432.ccr-25-1388 · ExternalCitation · doi-reference
Datopotamab deruxtecan, a novel TROP2-directed antibody–drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells
10.1158/1535-7163.mct-21-0206 · ExternalCitation · doi-reference
Potential mechanisms of interstitial lung disease induced by antibody–drug conjugates based on quantitative analysis of drug distribution
10.1158/1535-7163.mct-24-0267 · ExternalCitation · doi-reference
Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany
10.1177/17588359231200454 · ExternalCitation · doi-reference
Trop2-targeted therapy in breast cancer
10.1186/s40364-024-00633-6 · ExternalCitation · doi-reference
Sacituzumab govitecan in hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer
10.1200/jco.22.01002 · ExternalCitation · doi-reference
Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression
10.1200/jco.23.01409 · ExternalCitation · doi-reference
Datopotamab deruxtecan in advanced or metastatic HR+/HER2– and triple-negative breast cancer: results from the Phase I TROPION-PanTumor01 Study
10.1200/jco.23.01909 · ExternalCitation · doi-reference
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor–positive human epidermal growth factor receptor 2–negative breast cancer: primary results from TROPION-Breast01
10.1200/jco.24.00920 · ExternalCitation · doi-reference
Expression of Trop2 cell surface glycoprotein in normal and tumor tissues
10.1369/0022155411410430 · ExternalCitation · doi-reference
Trop-2 is a determinant of breast cancer survival
10.1371/journal.pone.0096993 · ExternalCitation · doi-reference
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
10.18632/oncotarget.4318 · ExternalCitation · doi-reference
Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
10.21037/atm-22-6266 · ExternalCitation · doi-reference
Tumor-associated calcium signal transducer 2 is required for the proper subcellular localization of claudin 1 and 7
10.2353/ajpath.2010.100149 · ExternalCitation · doi-reference
Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multicenter real-world analysis
10.3389/fonc.2024.1362641 · ExternalCitation · doi-reference
Mechanisms of ADC toxicity and strategies to increase ADC tolerability
10.3390/cancers15030713 · ExternalCitation · doi-reference
Canadian expert recommendations on safety overview and toxicity management strategies for sacituzumab govitecan based on use in metastatic triple-negative breast cancer
10.3390/curroncol31090422 · ExternalCitation · doi-reference
